Baicalein Suppresses Stem Cell-Like Characteristics in Radio- and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Resistance to both chemotherapy and radiation therapy is frequent in triple-negative breast cancer (TNBC) patients. We established treatment-resistant TNBC MDA-MB-231/IR cells by irradiating the parental MDA-MB-231 cells 25 times with 2 Gy irradiation and investigated the molecular mechanisms of acquired resistance. The resistant MDA-MB-231/IR cells were enhanced in migration, invasion, and stem cell-like characteristics. Pathway analysis by the Database for Annotation, Visualization and Integrated Discovery revealed that the NF-κB pathway, TNF signaling pathway, and Toll-like receptor pathway were enriched in MDA-MB-231/IR cells. Among 77 differentially expressed genes revealed by transcriptome analysis, 12 genes involved in drug and radiation resistance, including interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), were identified. We found that baicalein effectively reversed the expression of IFIT2, which is reported to be associated with metastasis, recurrence, and poor prognosis in TNBC patients. Baicalein sensitized radio- and chemoresistant cells and induced apoptosis, while suppressing stem cell-like characteristics, such as mammosphere formation, side population, expression of Oct3/4 and ABCG2, and CD44highCD24low population in MDA-MB-231/IR cells. These findings improve our understanding of the genes implicated in radio- and chemoresistance in breast cancer, and indicate that baicalein can serve as a sensitizer that overcomes treatment resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066 · cited 1×
“Breast cancer is the most prevalent cancer type worldwide and the second leading cause of cancer death for women, and over 60% of breast cancer patients receive radiation therapy [1].”
BackgroundTriple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 3×
“While only 15–20% of breast cancer patients are classified as TNBCs, TNBC patients present with factors related to poor prognosis and unfavorable features in histologic grade, tumor size, and metastasis [2,3].”
BackgroundInfluentialA cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“Cancer stem cells (CSCs), or tumor initiating cells (TICs), are a particular subpopulation of cells in cancers that are capable of self-renewal and differentiation into the heterogeneous lineages of cancer cells that comprise the tumor [11].”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 5×
“Cell surface markers or specific membrane transporters are used to identify CSCs. Cells expressing CD44highCD24low and CD133high on their surfaces have been suggested as breast CSCs [16,17].”
BackgroundInfluentialTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Flavonoids, Flavonoid Subclasses and Breast Cancer Risk: A Meta-Analysis of Epidemiologic Studies
Hui, C., Qi, X., Qianyong, Z., Xiaoli, P., Jundong, Z., & Mantian, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054318 · Cited by 245
Cited by
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 466
Chen, Y., Zhang, J., Zhang, M., Song, Y., Zhang, Y., Fan, S., Ren, S., Fu, L., Zhang, N., Hui, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.577 · Cited by 82
Talik Sisin, N. N., Abdul Razak, K., Zainal Abidin, S., Che Mat, N. F., Abdullah, R., Ab Rashid, R., Khairil Anuar, M. A., & Rahman, W. N. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s269214 · Cited by 36
Kim, D. K., Ediriweera, M. K., Davaatseren, M., Hyun, H. B., & Cho, S. K. (2022) · Food Science & Nutrition · doi:10.1002/fsn3.2702 · Cited by 33
“…MDA- MB- 231 cells, and radio- resistant triple- negative breast cancer MDA- MB- 231/IR established and characterized as previously described (Koh et al., 2019), human pancreatic cancer PANC- 1 cells, human hepatoblastoma HepG2 cells, breast cancer stem cell line MCF- 7SC established and…”
BackgroundSelf-citationMageau, E., Derbowka, R., Dickinson, N., Lefort, N., Kovala, A. T., Boreham, D. R., Tai, T. C., Thome, C., & Tharmalingam, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080589 · Cited by 12
“Additionally, baicalein induced dose-dependent apoptosis, highlighting its dual role as both a chemotherapeutic and radiosensitizing compound in the treatment of radiation-resistant breast cancer [29].”
Influential
Metadata
- Authors
- Koh, S. Y., Moon, J. Y., Unno, T., & Cho, S. K.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2019-03-14
- Volume
- 11
- Issue
- 3
- Pages
- 624
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2922122320
- Cited by
- 85
- References
- 7
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.